The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

Pfizer (NYSE:PFE) develops and sells biopharmaceutical products, including vaccines, treatments for infectious diseases, ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Keep in mind, though, that many steep dividend yields are due to the underlying stock having fallen, and Pfizer is a clear ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

Live Updates Live Coverage Has Ended Tuesday Wrap-up 4:27 pm The Vanguard S&P 500 ETF closed at 577.35 Tuesday, down 0.5%.

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...